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Abstract
Aims/hypothesis The aim of this study was to assess the risk
of death during hospital admission for diabetic ketoacidosis
(DKA) and, subsequently, following discharge. In addition,
we aimed to characterise the risk factors for multiple presen-
tations with DKA.
Methods We conducted a retrospective cohort study of all
DKA admissions between 2007 and 2012 at a university
teaching hospital. All patients with type 1 diabetes who were
admitted with DKA (628 admissions of 298 individuals) were
identified by discharge coding. Clinical, biochemical andmor-
tality data were obtained from electronic patient records and
national databases. Follow-up continued until the end of 2014.
Results Compared with patients with a single DKA admis-
sion, those with recurrent DKA (more than five episodes)
were diagnosed with diabetes at an earlier age (median 14
[interquartile range 9–23] vs 24 [16–34] years, p<0.001),
had higher levels of social deprivation (p=0.005) and higher
HbA1c values (103 [89–108] vs 79 [66–96] mmol/mol; 11.6%
[10.3–12.0%] vs 9.4% [8.2–10.9%], p<0.001), and tended to
be younger (25 [22–36] vs 31 [23–42] years, p= 0.079).
Antidepressant use was greater in those with recurrent DKA
compared with those with a single episode (47.5% vs 12.6%,
p=0.001). The inpatient DKA mortality rate was no greater
than 0.16%. A single episode of DKAwas associated with a
5.2% risk of death (4.1 [2.8–6.0] years of follow-up) com-
pared with 23.4% in those with recurrent DKA admissions
(2.4 [2.0–3.8] years of follow-up) (HR 6.18, p=0.001).
Conclusions/interpretation Recurrent DKA is associated with
substantial mortality, particularly among young, socially dis-
advantaged adults with very high HbA1c levels.
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Introduction
Despite incremental improvements in mortality associated
with diabetic ketoacidosis (DKA), 38% of deaths from
hyperglycaemic crises occur at home in young adults. In the
USA, there was very little change in the at-homemortality rate
between 1985 and 2002 [1]. However, declining mortality
rates from hyperglycaemic crises have been observed over a
similar timescale [1]. Recent estimates of inpatient DKAmor-
tality have varied between <1% [2] and up to 1.8% [3]. Type 1
diabetes continues to be associated with premature death and,
in Scottish adults younger than 50 years, DKA has been iden-
tified as the single biggest contributor to loss of life (29.4% in
men and 21.7% in women) [4]. Hospital admission for DKA
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is associated with social deprivation [5, 6], high HbA1c levels
[5–8], reduced concordance with insulin therapy [9] and
female sex [5]. Although several case series of patients with
‘brittle diabetes’ (characterised at least in part by recurrent
DKA) have been published [10–12], a robust definition of
‘brittle diabetes’ does not exist and no systematic assessment
of mortality risk, in the context of recurrent DKA, has been
conducted. We therefore sought to examine factors associated
with recurrent admissions for DKA, to assess the risk of
mortality during inpatient admissions for DKA and, for the
first time, to determine the risk of mortality in the years
following hospital discharge.
Methods
This was a retrospective cohort study including all people with
type 1 diabetes admitted with DKA to the Royal Infirmary of
Edinburgh, a large university teaching hospital, over a 6-year
period (2007–2012). Patients were identified from electronic
discharge coding (which included patients who died during an
admission). This was cross-checked against comprehensive
mortality data from the national Scottish Care Information–
Diabetes Collaboration (SCI-Diabetes) database (a dynamic
clinical information system containing >99% of diagnosed
diabetes cases in Scotland), over the same period, to ensure
any DKA deaths were not missed in the original data collec-
tion. Electronic patient records and the SCI-Diabetes database
were interrogated to record the date of diabetes diagnosis,
social deprivation status (using the Scottish Index of
Multiple Deprivation [SIMD], which comprises 6505
‘datazones’, where ‘1’ is the most deprived and ‘6505’ is the
least deprived) [13], the most recent HbA1c level, length of
inpatient hospital stay, laboratory variables on admission
(including glucose, hydrogen ion, lactate, urea, creatinine
and white cell count) and diabetes complications (micro- and
macrovascular).
The complete cohort included 628 admissions (298 indi-
viduals). All patients in Scotland have a unique patient iden-
tification number (Community Health Index), which was used
to obtain mortality data (date, cause and location) from
National Records Scotland. Data collection continued until
the end of 2014, resulting in a median mortality follow-up of
3.4 years (interquartile range [IQR] 2.3–5.3 years). Where
patients had more than one DKA admission, data from their
last admission was included for analysis. Mortality data are
presented for the entire cohort identified by hospital admis-
sions during the study period. Further analysis, investigating
the influence of the number of lifetime DKA admissions, was
limited to patients diagnosed with diabetes from 1981
onwards (when national data collection began). This popula-
tion was stratified into three groups: one lifetime DKA
episode, two to five lifetime DKA episodes and more than
five DKA episodes, based on preliminary analysis of
Kaplan–Meier survival curves.
All lifetime admissions (all Scottish hospitals) for DKA
were ascertained from Scottish Morbidity Record (SMR01)
coding from the Information Statistics Division of NHS
National Services, Scotland [5], and was limited to those pa-
tients diagnosed after 1981 (when SMR01 data collection be-
gan). Similarly, any hospital admissions for the treatment of
mental illness were recorded using SMR04 coding from the
Information Statistics Division. National primary-care-level
prescribing data have been collected in Scotland since 2009
(Prescribing Information System), and these data were inter-
rogated to establish whether patients had received antidepres-
sants, anxiolytics, antihypertensive agents, antiplatelet therapy
or statins.
Statistics The χ2 test was used for categorical univariate
analysis and the Kruskal–Wallis test was used for univariate
analysis of continuous data. Non-parametric tests were select-
ed as transformation did not provide satisfactory normal dis-
tribution, as determined by Kolmogorov–Smirnov tests.
Two-sided p values were used to assess group differences
and 0.05 was used as the threshold for significance.
Univariate survival analysis was carried out using logrank
tests for categorical predictors and univariate Cox models
for continuous predictors. Proportional hazards assumptions
were assessed using log(–log) plots for categorical predictors
in a Cox model with no obvious violations. The Cox model
was tested for the presence of interactions and none were
found to be significant. Multivariate variable selection was
performed using backward stepwise regression. Bonferroni
correction was applied to post hoc testing to adjust for multi-
ple comparisons. All statistical analyses were performed using
SPSS version 22 (IBM, Armonk, NY, USA). Data are shown
as median (IQR), unless otherwise stated.
Results
Differences between single and multiple DKA episodes
Lifetime national DKA admission data were available for all
patients diagnosed with diabetes from 1981 onwards (271
patients from the complete cohort of 298). These patients were
stratified into three groups based on the total number of DKA
admissions: single admission (n=96), two to five admissions
(n=111) and more than five admissions (n=64). Overall,
55% (n=164) of individuals presenting with DKAwere men
and no difference in the sexes was noted between the three
categories (26.0% of women had more than five DKA presen-
tations compared with 21.7% of men, p=0.186). Compared
with patients with a single admission, those with multiple
presentations had a longer duration of diabetes (median 12.8
[IQR 10.0–17.5] vs 7.6 [2.3–13.6] years, p<0.001) and were
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diagnosed with diabetes at a younger age (14 [9–23] vs 24
[16–34] years, p<0.001). Multiple DKA admissions were
more common in patients with higher levels of social depri-
vation (SIMD rank 1825 [813–3346] vs 2723 [1559–4310],
p= 0.005) and higher HbA1c levels (103 [89–108] vs 79
[66–96] mmol/mol; 11.6% [10.3–12.0%] vs 9.4%
[8.2–10.9%], p<0.001). Comparisons of other clinical vari-
ables can be seen in electronic supplementary material (ESM)
Table 1.
Overall, 13.1% (8/61) of patients with more than five DKA
admissions had experienced an inpatient admission for psy-
chiatric care, compared with 5.6% (6/108) and 4.3% (4/92) of
those with two to five and a single DKA admission, respec-
tively (p=0.092). Furthermore, 47.5% (29/61) of those with
more than five DKA admissions had received antidepressants,
compared with 27.8% in the intermediate (30/108) and 12.6%
(12/95) in the single-attender groups (p=0.001). No signifi-
cant relationships were observed with DKA admission fre-
quency and the use of other classes of medication (ESM
Table 2).
Inpatient DKA mortality rate Over 6 years, 628 DKA
admissions were identified, involving 298 individuals with
type 1 diabetes. The median age at presentation was 28 years
(IQR 22–40 years). No deaths were identified during inpatient
admissions for the management of DKA. To ensure our data
capture was complete, every death of a patient with type 1
diabetes registered to our outpatient clinic (153 deaths) was
reviewed across the study time period using our comprehen-
sive diabetes register. This revealed a single inpatient death
where DKA was reported as a contributory factor; the inpa-
tient DKA mortality rate was therefore, at most, 0.16%.
Subsequent mortality following hospital discharge (total
cohort) In patients with a prior DKA presentation, 44 deaths
(14.8%) were observed during follow-up (median 4.9 [IQR
3.3–6.7] years) in 298 individuals. The median age of death
was 45.9 years (IQR 30.8–58.0 years). Mortality rates were
significantly associated with the number of DKA presenta-
tions during the 6-year study period, and were highest in those
with more than four admissions (29.6% [8/27]), intermediate
in those with two to four admissions (18.3% [15/82]) and
lowest in those with a single admission (10.6% [20/189])
(p=0.016).
A total of 19 of these 44 deaths were of uncertain cause,
and were often unexpected and potentially attributable to
acute metabolic decompensation. The median age of these
patients was 31 years (range 20–63 years) (full cause-of-
death data are presented in ESM Fig. 1). Overall, 52.3%
(23/44) deaths occurred at home at a median age of 38 years
(IQR 27.7–52.3 years), compared with a median age of
57.7 years (IQR 40.5–61.4 years) in those dying in hospital
(p = 0.01). Ten deaths (eight at home) occurred within
2 months of the final DKA admission; all of these deaths were
unanticipated.
A range of clinical factors were associated with increased
mortality risk, including older age, longer diabetes duration,
prior DKA requiring intensive care admission, psychological
issues, neuropathy, previous cardiovascular disease, excess
alcohol intake and a longer length of stay during the last hos-
pital admission (Tables 1, 2). Prescription of an antidepres-
sant, at any time since 2009 (when national data collection
began, n=264), was associated with a trend towards increased
likelihood of death (HR 2.24, 95% CI 0.99, 5.12, p=0.055).
Social deprivation was not associated with mortality risk in
this cohort (Table 1).
Influence of lifetime DKA admissions Overall, 23.4%
(15/64) of those with more than five lifetime DKA admissions
died over a median 2.4 year (IQR 2.0–3.8 years) follow-up
period (HR 6.18 [95% CI 2.1, 18.3], p=0.001; Fig. 1). Death
occurred in 13.5% (15/111) of those with two to five admis-
sions (HR 3.02 [95% CI 1.1, 8.4; reference is single DKA],
p=0.035) over a median of 3.7 years (IQR 2.4–5.5 years). A
single lifetime DKA admission was associated with a 5.2%
(5/96) risk of death during the follow-up period (median 4.1
[IQR 2.8–6.0] years). Median age at death was significantly
lower in those with more than five DKA admissions (32 [IQR
23–39] years) than in those with two to five admissions
(median 53 [IQR 40–58] years) or a single admission (median
53 [IQR 38–66] years) (p=0.014). The prevalence of cardio-
vascular disease was not independently associated with mor-
tality. Multivariate analysis identified greater number of DKA
admissions, longer diabetes duration, previous psychiatric
admissions and older age at diagnosis as independent predic-
tors of death (Table 3).
Discussion
The most striking finding from this investigation is the sub-
stantial short-term risk of death associated with recurrent
DKA admissions in patients with type 1 diabetes. Recurrent
DKA disproportionately affects young people, typically those
with greater social deprivation and markedly elevated HbA1c
levels. In keeping with other modern cohorts [2, 3], we found
a low rate of inpatient mortality in patients presenting with
DKA. Although recent evidence suggests suboptimal adher-
ence to DKA management protocols in the UK [14], inpatient
outcomes are almost always satisfactory. However, the fre-
quency of subsequent sudden death at home, particularly in
young people, is unacceptably high.
In the current study, we identified social deprivation as
being significantly associated with an increased likelihood of
multiple lifetime DKA presentations, as has previously been
demonstrated in a cohort of 23,479 Scottish patients with type
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1 diabetes, where the risk of admission for DKAwas 4.5-fold
higher for those in the most deprived quintile compared with
the least deprived quintile, independently of other recognised
risk factors such as HbA1c [5]. This is broadly consistent with
findings from the US T1D Exchange Clinic Registry, which
identified lower income, lack of private medical insurance and
lower educational attainment as independent risk factors for
DKA admission [6]. Data from the T1D Exchange Clinic
Registry also confirm a progressive increase in the likelihood
of DKAwith increasing HbA1c [6]. Younger age at diagnosis
of diabetes, and particularly during the teenage years, appears
to be associated with an increased risk of multiple DKA pre-
sentations. Case series describing the experiences of patients
with ‘brittle diabetes’ have recognised the potential impact of
adjusting to a diagnosis of diabetes during adolescence [12].
In those diagnosed at a younger age, longer duration of
diabetes does not account for the higher frequency of DKA
presentations.
In the current study, almost 50% of the most frequent DKA
attenders had received an antidepressant since 2009 and, al-
though the absolute numbers were low, there was a trend to-
wards a greater likelihood of admission for the treatment of
psychiatric illness. Prior antidepressant prescription was asso-
ciated with a higher risk of death and previous psychiatric
inpatient care was independently predictive of death. The na-
tionwide German/Austrian Diabetes Survey recently reported
higher DKA rates in patients receiving antipsychotic medica-
tion [15] and, in a US series, depression and substance abuse
were more common in those with multiple DKA presentations
[16].
Most strikingly, a greater than one in five risk of death was
observed in those with the highest frequency of DKA
Table 1 Clinical and laboratory
variables at last DKA admission,
comparing survivors with patients
who subsequently died
Variable Alive (n = 254) Deceased (n = 44) p value
Age at last presentation, years 28 (21–42) 43 (30–55) <0.001
Diabetes duration, years 10 (5–16) 13 (9–27) 0.004
HbA1c, mmol/mol 90 (74–107) 82 (71–97) 0.220
HbA1c, % 10.4 (8.9–11.9) 9.7 (8.6–11.0) 0.220
SIMD rank, out of 6505 2677 (1423–4019) 2695 (1349–4333) 0.969
Length of stay at last DKA admission, days 2 (1–3) 4 (2–9) <0.001
Hydrogen ion, nmol/l 72 (56–104) 78 (55–109) 0.423
Lactate, mmol/l 3.3 (2.2–4.7) 3.2 (1.8–3.9) 0.258
Glucose, mmol/l 33.5 (24.7–43.5) 36.0 (28.3–55.3) 0.067
ALT, μkat/l 0.35 (0.25–0.55) 0.35 (0.25–0.96) 0.468
Urea, mmol/l 8.3 (6.2–11.7) 14.2 (8.3–19.8) 0.002
Creatinine, μmol/l 121 (94–158) 159 (110–242) 0.002
White cell count, ×109/l 18.3 (11.6–25.9) 14.8 (10.2–19.8) 0.055
Data are medians (IQR) and were compared using the Mann–Whitney U test
ALT, alanine aminotransferase
Table 2 Categorical clinical var-
iables, comparing survivors with
patients who subsequently died







Psychological issues 109 (36.6) 86 (33.9) 23 (52.3) 2.60 (1.33, 5.08) 0.005
Retinopathy 126 (42.3) 106 (41.7) 20 (45.5) 0.77 (0.39, 1.53) 0.459
Nephropathy 33 (11.1) 24 (9.4) 9 (20.5) 1.53 (0.59, 3.93) 0.383
Peripheral neuropathy 64 (21.5) 47 (18.5) 17 (38.6) 2.36 (1.15, 4.82) 0.018
Autonomic neuropathy 36 (12.1) 25 (9.8) 11 (25.0) 2.47 (1.03, 5.95) 0.044
Ischemic heart disease 13 (4.4) 8 (3.1) 5 (11.4) 3.07 (0.94, 10.02) 0.063
Stroke/PVD 15 (5.0) 9 (3.5) 6 (13.6) 3.83 (1.35, 10.85) 0.012
Excess alcohol intake 41 (13.8) 30 (11.8) 11 (25.0) 3.83 (1.88, 7.82) <0.001
Prior DKA admission to ITU 38 (12.8) 28 (11.0) 10 (22.7) 2.28 (1.03, 5.01) 0.041
Data are n (%), unless otherwise stated
ITU, intensive therapy unit; PVD, peripheral vascular disease
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presentation over a median 2.4 years of follow-up, compared
with a one in 20 risk of death in those with a single DKA
admission over a median of 4 years. This represents a substan-
tially elevated risk of death when compared with the Scottish
type 1 diabetes population. Recently published national data
reported mortality rates of 3.5 and 4.3 per 1000 person-years
in men and women with type 1 diabetes, respectively, in the
30–34 years age bracket [4]. We identified frequency of DKA
as an independent risk factor for death in multivariate analysis
whilst, perhaps surprisingly, prior admissions for cardiovascu-
lar disease was not. This is potentially a reflection of the rel-
atively low proportion of deaths due to cardiovascular causes;
which might also explain why no significant differences were
noted in social deprivation scores between those who died and
survivors. The prevalence of prior cardiovascular disease was
relatively low in this population, which therefore might have
been underpowered to detect a significant difference. Modest
associations were identified between mortality and neuropa-
thy and nephropathy, but not retinopathy. This might reflect
the high prevalence of retinopathy across both groups and
failure to account for the broad spectrum of severity of this
condition, from background changes to sight-threatening
disease.
LimitationsWhilst including two separate analyses (the com-
plete cohort and a subset diagnosed with diabetes after 1981)
might appear unnecessarily complicated, we chose to present
both as the restricted dataset is strengthened by comprehen-
sive national data on lifetime DKA admissions. However,
solely limiting our analysis to these patients would have ex-
cluded those diagnosed with diabetes prior to the onset of
national data collection in 1981, and would have distorted
the total mortality figures. It is recognised that studies reliant
on national data collection often under-report diabetes-related
admissions [17]; this pitfall was avoided here through a com-
bination of hospital-level and national data collection.
A significant benefit of the single-centre study design was
our ability to carefully verify the quality of the included data,
although reporting from a single centre does leave the
generalisability of these results open to question. In defence
of the wider applicability of these data, the characteristics of
our patients seem broadly comparable with those described in
several other series [6–8]. Despite a relatively small cohort
size, we have been able to describe a number of significant
associations in relation to the risks of both recurrent DKA and
subsequent mortality.
As with any study reliant on death-certification data, rec-
ognition of the frequent lack of clarity in relation to ‘cause of
death’ is necessary. The category we chose to describe as
‘unclear’ was the single largest cause of death and included
unconfirmed hypoglycaemia and DKA (at home), as well as
presumed sudden cardiac death. However, our most striking
finding in relation to mortality was the high rate of death at
home in very young patients, which was unequivocal.
Having recognised the significant mortality risk associated
with recurrent DKA, it is important that these findings are
verified, ideally through national registry data. Those diag-
nosed with diabetes in adolescence and those with mental
health issues appear to be at particularly high risk for recurrent
DKA, and efforts are required to develop effective support
strategies. In the UK, attendance at a structured education
programme that promotes flexible intensive insulin therapy
(DAFNE) has been associated with a 61% reduction in
DKA in the following 12 months [18]; however, it can be
difficult to encourage those who have elected not to engage
with specialist services to commit to a 5-day education pro-
gramme. A potentially complementary strategy, targeting pa-
tients with persistently suboptimal HbA1c levels (in type 1 and
2 diabetes), employs a combined medical, psychological and


















Fig. 1 Kaplan–Meier curves stratified by lifetime DKA admissions. Blue
line, single admission; green line, two to five admissions; red line, more
than five admissions. Vertical lines indicate censored data
Table 3 HRs for death following DKA, presented for all independently
predictive variables from a multivariate Cox proportional hazard model
Variable HR 95% CI for HR p value
Lower Upper
Diabetes duration (years) 1.069 1.018 1.121 0.007
Single DKA admission Ref. Ref. Ref. –
Two to five DKA admissionsa 3.016 1.078 8.436 0.035
More than five DKA admissionsa 6.176 2.089 18.256 0.001
Psychiatric inpatient admission 5.687 2.620 12.345 <0.001
Age at diagnosis 1.044 1.019 1.070 0.001
a For DKA frequency, single DKA admission is the reference
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social support approach (‘3 Dimensions of Care for
Diabetes’); this has been reported to result in significant re-
ductions in emergency department attendances and inpatient
admissions [19]. Longitudinal studies of ‘brittle diabetes’ sug-
gest that patients eventually cease presenting with recurrent
DKA, anecdotally often following positive life events, but
frequently develop a significant burden of chronic diabetes
complications [11, 12]. Considerable challenges remain in
preventing early death and later complications in this vulner-
able group.
Acknowledgements Statistical analysis support was provided by R.
Sisk, Information Analyst, NHS National Services Scotland. This study
was previously presented as an oral communication at the 2015American
Diabetes Association Scientific Sessions.
Funding This research received no specific grant from any funding
agency in the public, commercial or not-for-profit sectors.
Duality of interest statement The authors declare that there is no du-
ality of interest associated with this manuscript.
Contribution statement FWG and KAL conceived this study with
subsequent input from WLT and JG in developing study design and
contributing to data collection and analysis. FWG wrote the initial draft
of the manuscript with revisions provided from all authors. The final
manuscript was approved by all authors. FWG is the guarantor of this
work.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Wang J, Williams DE, Venkat Narayan KM, Geiss LS (2006)
Declining death rates from hyperglycemic crisis among adults with
diabetes, U.S., 1985–2002. Diabetes Care 29:2018–2022
2. Kitabachi AE, Miles JM, Umpierrez GE, Fisher JN (2009)
Hyperglycemic crises in adult patients with diabetes. Diabetes
Care 32:1335–1343
3. Wright J, Ruck K, Rabbitts R et al (2009) Diabetic ketoacidosis
(DKA) in Birmingham, UK, 2000–2009: an evaluation of risk fac-
tors for recurrence and mortality. Br J Diabetes Vasc Dis 9:278–282
4. Livingstone SJ, Levin D, Looker HC et al (2015) Estimated life
expectancy in a Scottish cohort with type 1 diabetes, 2008–2010.
JAMA 313:37–44
5. Govan L,Maietti E, TorsneyB et al (2012) The effect of deprivation
and HbA1c on admission to hospital for diabetic ketoacidosis in
type 1 diabetes. Diabetologia 55:2356–2360
6. Weinstock RS, Xing D, Maahs DM et al (2013) Severe hypoglyce-
mia and diabetic ketoacidosis in adults with type 1 diabetes: results
from the T1DExchange clinic registry. J Clin EndocrinolMetab 98:
3411–3419
7. Butalia S, Johnson JA, Ghali WA, Rabi DM (2013) Clinical and
socio-demographic factors associated with diabetic ketoacidosis
hospitalization in adults with type 1 diabetes. Diabet Med 30:
567–573
8. Cooper H, Tekiteki A, Khanolkar M, Braatvedt G (2016) Risk
factors for recurrent admissions with diabetic ketoacidosis: a case-
control observational study. Diabet Med 33:523–528
9. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM,
NewtonRW (1997)Adherence to insulin treatment, glycaemic control,
and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/
MEMO Collaboration Diabetes Audit and Research in Tayside
Scotland Medicines Monitoring Unit. Lancet 350:1505–1510
10. Gill GV, Alberti KG (1991) Outcome of brittle diabetes. BMJ 303:
285–286
11. Cartwright A, Wallymahmed M, Macfarlane IA, Wallymahmed A,
Williams G, Gill GV (2011) The outcome of brittle type 1 diabe-
tes—a 20 year study. QJM 104:575–579
12. Kent LA, Gill GV, Williams G (1994) Mortality and outcome of
patients with brittle diabetes and recurrent ketoacidosis. Lancet 344:
778–781
13. Scottish Government (2016) Scottish index of multiple deprivation.
Available from www.gov.scot/Topics/Statistics/SIMD, accessed 26
April 2016
14. Dhatariya KK, Nunney I, Higgins K, SampsonMJ, Iceton G (2015)
National survey of the management of diabetic ketoacidosis (DKA)
in the UK in 2014. Diabet Med 33:252–260
15. Galler A, Bollow E,MeusersM et al (2015) Comparison of glycemic
and metabolic control in youth with type 1 diabetes with and without
antipsychotic medication: analysis from the Nationwide German/
Austrian Diabetes Survey (DPV). Diabetes Care 38:1051–1057
16. Randall L, Begovic J, Hudson M et al (2011) Recurrent diabetic
ketoacidosis in inner-city minority patients. Diabetes Care 34:
1891–1896
17. Anwar H, Fischbacher CM, Leese GP et al (2011) Assessment of
the under-reporting of diabetes in hospital admission data: a study
from the Scottish Diabetes Research Network Epidemiology
Group. Diabet Med 28:1514–1519
18. Elliott J, Jacques RM, Kruger J et al (2014) Substantial reductions
in the number of diabetic ketoacidosis and severe hypoglycaemia
episodes requiring emergency treatment lead to reduced costs after
structured education in adults with type 1 diabetes. Diabet Med 31:
847–853
19. Doherty AM, Gayle C, Morgan-Jones R et al (2015) Improving
quality of diabetes care by integrating psychological and social care
for poorly controlled diabetes: 3 Dimensions of Care for Diabetes.
Int J Psychiatry Med 51:3–15
Diabetologia (2016) 59:2082–2087 2087
